Potential Drug Suppresses a Key Hallmark of Alzheimers
The loss of synaptic connections is a key predictor of Alzheimer's disease. This irreversible neurodegenerative brain disorder destroys memory and thinking, eventually destroying the ability to perform simple everyday tasks. Amyloid-β is a peptide that is especially prone to misfolding and aggregation, which abnormally accumulates in AD patients, initiating synaptic dysfunction. Synaptic loss and the accumulation of Aβ strongly correlate with impairment in AD, yet the mechanism linking the origin of this loss and the pattern it follows remains unclear.
Upon taking Introduction to Neuroscience, I had an assignment in which I explored recent news about Alzheimer's disease. This study targeted arginine-Aβ in mice, how it accumulates early, drives inflammation, and precedes behavioral impairment. This past semester, I was able to listen to Dr. Delgado explain his research. In the study “Pin1 binding to phosphorylated PSD-95 regulates the number of functional excitatory synapses," Dr. Delgado and colleagues suggest a molecular mechanism by which the phosphorylation of PSD- 95, a postsynaptic density protein, recruits Pin-1 and decreases the number of functional synapses. When reading his research article, I began to understand the connection that can be made to findings I had previously read about.
The study, "Oral administration of arginine suppresses Aβ pathology in animal models of Alzheimer’s disease," follows the study of a potential drug that can reverse aggregates present in Alzheimer's cases. The team evaluated Aβ, a key hallmark of Alzheimer's, in different animals carrying different mutations. Scientists tested the peptide to see if the drug, arginine, stops the accumulation of Aβ. Findings from Kindai University suggest that reduced Aβ aggregation leads to less kinase overactivation. The less pathological phosphorylation leads to less Pin1 recruitment, and the preserved PSD- 95 maintains excitatory synapses. Aβ aggregation likely leads to the phosphorylation events that enable Pin1- mediated synaptic loss. The results were promising as both accumulation and toxicity were mitigated, as well as behavioral performance improvement and a reduction of neuroinflammation.
These findings lend support to a theory where incorrect phosphorylation signaling triggered by Aβ aggregation destabilizes postsynaptic scaffolding through Pin1and PSD-95 interactions, resulting in synapse loss. This synaptic loss may be reversed through interventions such as the drug arginine, which has shown to suppress aggregation and indirectly protect synapses by preventing activation of this destabilizing pathway. These findings open new possibilities for developing new strategies and treatments for neurodegenerative diseases.
Together, these studies highlight how Alzheimer’s disease progression may be driven not only by the presence of amyloid-β, but by the molecular signaling cascades it initiates at the synapse. By linking Aβ aggregation to abnormal phosphorylation events that destabilize postsynaptic scaffolding through Pin1 and PSD-95, this work helps clarify how early synaptic loss emerges and spreads before widespread disease progression. Importantly, the ability of arginine to suppress Aβ aggregation and reduce downstream pathological signaling suggests that targeting early aggregation events may preserve synaptic integrity and slow cognitive decline. Because aggregations and protein misfolding are central to a great variety of neurodegenerative diseases, these findings can have broader applications beyond just Alzheimer’s. Together, these findings emphasize the value of combining molecular, synaptic, and behavioral approaches to better understand Alzheimer’s disease and to guide the development of disease-modifying therapies aimed at protecting synaptic connections, such as arginine. Alzheimer’s breakthroughs bring us closer to slowing and reversing memory loss. It is compelling as these advances offer hope for protecting and preserving the moments that matter most.
References
Delgado, J. Y.; et al. Pin1 Binding to Phosphorylated PSD-95 Regulates the Number of Functional Excitatory Synapses. Neurochemistry International 2025, 186, 105835. https://doi.org/10.1016/j.neuint.2025.105835
No comments:
Post a Comment